These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 16757288

  • 1. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, Bonora S, Motta A, Luzi K, Pecorari M, Gennari W, Masetti M, Gerunda GE, Esposito R.
    Transplant Proc; 2006 May; 38(4):1138-40. PubMed ID: 16757288
    [Abstract] [Full Text] [Related]

  • 2. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M, Clay PG, Anderson PL, Glaros AG.
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, Fung JJ.
    Liver Transpl; 2003 Mar; 9(3):239-47. PubMed ID: 12619020
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Telzir (fosamprenavir).
    Wilkins E.
    J HIV Ther; 2004 Nov; 9(4):87-91. PubMed ID: 15731740
    [Abstract] [Full Text] [Related]

  • 15. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117
    [Abstract] [Full Text] [Related]

  • 16. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
    Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ.
    Clin Infect Dis; 2004 Aug 15; 39(4):591-4. PubMed ID: 15356829
    [Abstract] [Full Text] [Related]

  • 17. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.
    Antimicrob Agents Chemother; 2006 Apr 15; 50(4):1578-80. PubMed ID: 16569890
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.